Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
10.1186/s13063-019-3259-x Trials 20 FontanellaR
ICV injection of the specific GLP-1-receptor antagonist, exendin (9-39), blocked the inhibitory effect of GLP-1 on food intake
In 1992, a proof-of-concept study first suggested the potential of GLP-1 as an anti-diabetes drug, as a 3-hour continuous intravenous GLP-1 infusion significantly lowered the meal-related insulin requirement in patients with diabetes
Most commercial insurance plans that cover GLP-1 for weight loss require prior authorization documenting: BMI at or above 30 (or 27 with a weight-related condition like hypertension, type 2 diabetes, dyslipidemia, or sleep apnea), and in some cases, documented prior attempts at lifestyle modification
US$ 23.76
US$ 23.80
US$ 25.32
US$ 20.71
